Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline exercises option for cancer drug
As part of its June 1996 agreement with GSK, Human Genome Sciences granted a 50/50 co-development and co-promotion option to GSK for certain human therapeutic products that complete
As part of its June 1996 agreement with GSK, Human Genome Sciences granted a 50/50 co-development and co-promotion option to GSK for certain human therapeutic products that complete
Researchers hope that the drug could provide a dramatic reduction in the impact of malaria, relieving 10% of people infected with this debilitating and often fatal disease, which
Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics’ antibody-drug-conjugate (ADC) technology. “We’re pleased that Seattle Genetics
Currently, the only injectable form of diclofenac in Europe and other parts of the world is Voltarol. However, one limitation of the current European marketed form of the
The study is part of an ongoing effort to fight disease by manipulating energy regulation of cells, an essential process for keeping cells from dying off too quickly.
Located in the spiraled cochlea, the hearing portion of the inner ear, the hair cells transform the mechanical vibrations that enter the ear in the form of sound
The treatment contains a common virus called the reovirus which is able to replicate in cancer cells with an activated Ras pathway, without harming healthy cells. The Ras
The company has begun enrollment into a phase II study into its lead compound, CX-717, in this indication. CX-717 is expected to treat the memory and thinking disorders
The drug, sodium stibogluconate (SSG), used in the past to treat leishmaniasis, a skin disorder found mostly in tropic and sub-tropic developing countries, is now in clinical trials
Called cyclic alkyl amino carbenes or CAACs, the molecules attach themselves to metals, such as palladium, to form highly efficient catalysts that allow chemical transformations otherwise considered impossible.